Bass Vows to Keep Fighting U.S. Drug Patents After Setbacks
- Hayman Capital founder calls Patent Office `kangaroo court'
- Hedge-fund manager still challenging Acorda, Biogen drugs
This article is for subscribers only.
Hedge-fund manager Kyle Bass isn’t taking his early losses to the drug industry lightly.
The Hayman Capital Management founder claims the U.S. Patent and Trademark Office is purposefully denying his challenges to drug patents because it finds him “too disruptive.”